Ovarian cancer staging: What the surgeon needs to know

Abstract

Ovarian cancer (OC) is the leading cause of gynecological cancer death, and most cases are diagnosed at advanced stages due to a nonspecific and insidious clinical presentation. Radiologists play a critical role in the decision of which patients are candidates for primary debulking surgery and who may benefit from neoadjuvant chemotherapy. This pictorial review summarizes the dissemination patterns of OC, main imaging findings of metastatic disease, and which findings may alter the treatment plan or predict suboptimal tumor resection.

Baohuoside I inhibits resistance to cisplatin in ovarian cancer cells by suppressing autophagy via downregulating HIF‐1α/ATG5 axis

“…Ovarian cancer is a common kind of cancer that is typically detected later in its progression. 1 Nowadays, the most common methods of treating ovarian cancer are chemotherapy and cytoreductive surgery; however, the therapeutic effect remains unsatisfactory. 2 The majority of patients still suffer from progressive and recurrent ovarian cancer owing to chemotherapy resistance, despite tremendous advances in understanding the pathogenic underpinnings of disease.…”

“…Ovarian cancer is a common kind of cancer that is typically detected later in its progression 1 . Nowadays, the most common methods of treating ovarian cancer are chemotherapy and cytoreductive surgery; however, the therapeutic effect remains unsatisfactory 2 .…”